Tuesday, October 8, 2024
Today's Paper

CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

Completion of cash acquisition of licenced cord blood bank expanding CytoMed's strategy to cord blood-derived biologics through its subsidiary, LongevityBank Pte Ltd

Register to read this story and more for free.

Signing up for an account helps us improve your browsing experience.

Continue

See our subscription options.

Already have an account? Log in here